FindTrial
Sign In

Effect of remazolam toluene sulfonate in general anesthesia

Effect of remazolam toluene sulfonate in general anesthesia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097878
Enrollment
Unknown
Registered
2025-02-26
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Group C:Propofol is used during general anesthesia
Group D:Remazolam is used during general anesthesia

Sponsors

Sir Run Run Hospital Affiliated to Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Patients receiving general anesthesia for elective surgery; (2) Patients aged 18-85 with complete clinical records; (3) ASA classification I-III.

Exclusion criteria

Exclusion criteria: (1) Patients with a history of allergy to the experimental drug; (2) general anesthesia contraindications; (3) Patients with heart, lung, liver, kidney, blood and other important system diseases; (4) Patients with communication or cognitive impairment.

Design outcomes

Primary

MeasureTime frame
Blood pressure;Heart rate;Blood oxygen saturation;—

Secondary

MeasureTime frame
BIS;Vasoactive drugs and narcotic drugs dosage;PACU residence time;Duration of anesthesia;Duration of operation ;Postoperative delirium;Nausea and vomiting;NRS score;Postoperative adverse reaction;Postoperative recovery quality;—

Countries

China

Contacts

Public ContactZheng Longbin

Sir Run Run Hospital Affiliated to Nanjing Medical University

272425852@qq.com+86 180 6175 0597

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026